Q4 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Analysts at Leerink Partnrs cut their Q4 2024 earnings estimates for shares of Illumina in a research report issued on Monday, November 4th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings of $0.89 per share for the quarter, down from their prior forecast of $0.93. The consensus estimate for Illumina’s current full-year earnings is $3.62 per share. Leerink Partnrs also issued estimates for Illumina’s Q1 2025 earnings at $0.84 EPS, Q2 2025 earnings at $0.97 EPS, Q3 2025 earnings at $1.08 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.14 EPS and FY2026 earnings at $4.92 EPS.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 earnings per share.

Other equities analysts have also issued reports about the company. Robert W. Baird lifted their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday. Piper Sandler dropped their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Finally, Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price target for the stock from $120.00 to $154.00 in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus price target of $162.18.

Illumina Trading Up 2.2 %

NASDAQ ILMN opened at $155.15 on Thursday. The firm has a market capitalization of $24.72 billion, a PE ratio of -15.58 and a beta of 1.13. The business’s 50-day moving average price is $137.27 and its two-hundred day moving average price is $123.12. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina has a 12 month low of $89.00 and a 12 month high of $156.66.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ILMN. Prospera Financial Services Inc lifted its holdings in shares of Illumina by 2.8% in the third quarter. Prospera Financial Services Inc now owns 28,808 shares of the life sciences company’s stock valued at $3,757,000 after purchasing an additional 783 shares in the last quarter. Whalen Wealth Management Inc. bought a new position in Illumina during the 3rd quarter valued at $480,000. Caprock Group LLC boosted its holdings in Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares during the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in Illumina during the 3rd quarter worth $224,000. Finally, LMR Partners LLP bought a new stake in shares of Illumina in the 3rd quarter worth $2,776,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.